Filing Details
- Accession Number:
- 0000899243-19-025369
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-10-09 16:53:12
- Reporting Period:
- 2019-10-07
- Accepted Time:
- 2019-10-09 16:53:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1734517 | Viela Bio Inc. | VIE | Pharmaceutical Preparations (2834) | 1231 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 901832 | Plc Astrazeneca | 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge X0 CB2 0AA | No | No | Yes | No | |
| 1362825 | Ltd Uk Astrazeneca | 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge X0 CB2 0AA | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-10-07 | 14,225,324 | $0.00 | 14,225,334 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-10-07 | 425,000 | $19.00 | 14,650,334 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2019-10-07 | 14,225,324 | $0.00 | 14,225,324 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis.
- All of these securities are owned by AstraZeneca UK Limited, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca UK Limited, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.
- Reflects shares purchased in the Issuer's initial public offering.
- The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
- Not applicable.
Billionaire Hedge Funds
